Medivir Q2 2025 - Awaiting Phase IIb

Redeye comments on Medivir’s Q2 report. The quarter was somewhat uneventful, but the company has made further progress and is essentially ready for the planned pivotal phase II study in liver cancer. The only thing missing is funding.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/